Xencor (Monrovia, CA) has appointed Jeffrey D. Bloss, MD, chief medical officer. Bloss will direct Xencor's clinical and preclinical development strategies.
Xencor (Monrovia, CA) has appointed Jeffrey D. Bloss, MD, chief medical officer. Bloss will direct Xencor's clinical and preclinical development strategies. He will be responsible for building the company's clinical development team and for the design and implementation of studies to evaluate the company's pipeline of novel antibody and protein therapeutics. Most recently, Bloss was the vice president of clinical development at Onyx Pharmaceuticals, Inc., where he led the development for sorafenib.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Oligonucleotide Analysis in Pharmaceutical Quality Control
January 14th 2025Melting point determination using ultraviolet-visible (UV-Vis) spectrophotometry can be used as a sequence-specific method for identifying therapeutic oligonucleotides in pharmaceutical quality control. This method offers a simple, highly selective approach to differentiate between isomers and ensure the integrity of oligonucleotide active pharmaceutical ingredients (APIs) and drug products.